Biliary Tract Malignancy, FISH-994

Test info

  
Biliary Tract Malignancy, FISH
  
994
  
LAB994
  
MSO
  
Bile Duct Cancer, FISH
Bile Duct Cytology
Bile Duct Stricture Malignancy, FISH
BILAO
Cholangiocarcinoma, FISH
Pancreatobiliary FISH
  

Assessing bile duct brushing or hepatobiliary brushing specimens for malignancy.

Specimen

  
Bile duct brushing
Bile duct aspirate
Hepatobiliary brushing
Hepatobiliary aspirate
  
  
Entire vial
  
20 mL
  
  • Place specimen in Cytolyt vial. If the specimen is a brushing, submit the brush in the fixative. Specimen should be placed in fixative vial immediately after collection.
  • Label with collection site.
  
  

Specimen source is required.

 

  

Refrigerated (preferred) - 3 weeks

 

  
  • Pancreatic mass, cyst, or fine-needle aspiration (FNA)

Performance

  
Mayo Clinic Laboratories (BILAO): R-NX
  
Mo - Fr
  
7 - 10 days
  

Fluorescence In Situ Hybridization (FISH)

Clinical and Interpretive info

  

No abnormality detected by fluorescence in situ hybridization.

An interpretive report will be provided.

  

Endoscopic retrograde cholangiopancreatography (ERCP) is used to examine patients with biliary tract obstruction or stricture for possible malignancy. Biopsies and cytologic specimens are obtained at the time of ERCP. Cytologic analysis complements biopsy by sometimes detecting malignancy in patients with a negative biopsy. Nonetheless, a number of studies suggest that the overall sensitivity of bile duct brushing and bile aspirate cytology is quite low.

Fluorescence in situ hybridization (FISH) is a technique that utilizes fluorescently labeled DNA probes to examine cells for chromosomal alterations. FISH can be used to detect cells with chromosomal changes (eg, aneuploidy) that are indicative of malignancy. Studies in our laboratory indicate that the sensitivity of FISH to detect malignant cells in biliary brush specimens is superior to that of conventional cytology.

  
A positive FISH result does not identify location or type of malignancy. FISH abnormalities may be associated with high-grade dysplasia or carcinoma in situ. Cytology and biopsy may help clarify such situations

Billing

  
88377
  
Result: 95229-1

Tracking

  
11/01/2017
  
05/31/2023
  
05/31/2023